LLY logo

Eli Lilly and Company

LLY
Healthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48

About

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Stock Price

+44.4%(1Y)
1M
+15.8%
3M
+14.2%
6M
+42.8%
YTD
+26.0%
1Y
+40.1%
3Y
+118.7%
5Y
+419.7%

Pipeline Summary

500 total trials
166
Phase 1
136
Phase 2
135
Phase 3
50
Phase 4
Terminated: 40Completed: 388Recruiting: 33Unknown: 7Active: 17Withdrawn: 8Not Yet Recruiting: 4Approved: 1Available: 1By Invitation: 1

Active Trials (50)

A Study of LY4178256 in Healthy Participants
NCT07698210Healthy Volunteers
Phase 1Recruiting
Enrollment: 88 participants
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure
Phase 1Recruiting
Enrollment: 90 participants
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis
Phase 3Recruiting
Enrollment: 252 participants
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity
Phase 3Active
Enrollment: 600 participants
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3Active
Enrollment: 10,000 participants

BioScore

7.4/10
Buy

Key Facts

Market Cap$1273.77B
Employees50,000 (+6% YoY)
CEODavid A. Ricks
IPO DateJun 1, 1972
Beta0.45
52-Week Range$850.51 – $1453
Avg Volume2,586,394
ExchangeNYSE
Websitelilly.com

Ownership

Float90.1%
Shares Outstanding940.7M

Recent Insider Trades

Ricks David AGIFT
Nov 3, 202623,538 shares
Skovronsky DanielGIFT
Nov 2, 2026119 shares
Hakim AnatSELL
Nov 2, 20265,000 shares @ $1402.52
Montarce LucasOPTION EX.
Nov 1, 20261,610 shares
Montarce LucasTAX W/H
Nov 1, 2026677.593 shares @ $1417.54

Peers

ABBVAbbVie Inc.
$514.78B
AMGNAmgen Inc.
$248.92B
AZNAstraZeneca PLC
$289.14B
JNJJohnson & Johnson
$664.95B
MRKMerck & Co., Inc.
$361.96B
NVONovo Nordisk A/S
$177.74B
NVSNovartis AG
$307.00B
PFEPfizer Inc.
$167.51B
Data last updated: Nov 9, 2026, 04:20 AM